Company Overview and News

1
Belle Corp’s earnings up thanks to City of Dreams

2018-07-27 bworldonline - 1
BELLE Corp.’s attributable profit expanded by 10% in the three months ending June, driven by higher earnings of the City of Dreams Manila.
PLC

2
Premium Leisure income rises 12% in Q1

2018-04-24 bworldonline - 2
PREMIUM Leisure Corp. (PLC) reported its attributable net income increased by 12% in the first quarter, as higher interest income and dividends offset a drop in revenues.
LOTO PLC

 
City of Dreams Manila expansion planned

2018-04-24 business.inquirer.net
Leisure estate and gaming group Belle Corp. has submitted a proposal to the Melco group to expand the existing City of Dreams Manila (CoD Manila) integrated gaming resort using a one-hectare land adjacent to the property.
PLC

6
Belle proposes to expand City of Dreams Manila

2018-04-23 bworldonline - 1
BELLE CORP. seeks to expand its leisure and tourism offerings across the country, starting with the addition of hotel and non-gaming operations in the City of Dreams Manila to meet the demand for more accommodations inside Entertainment City.
PSKXF PLC PHSXY PSE

5
Premium Leisure earns P1.76 billion in 2017 as City of Dreams revenues rise

2018-03-22 bworldonline
PREMIUM LEISURE Corp. (PLC) grew its attributable profit by 83% in 2017, fueled by higher gaming revenues from resort and casino complex City of Dreams Manila.
LOTO PSKXF PLC PHSXY PSE

 
PLC profit jumps 83% on strong City of Dreams revenues

2018-03-22 bworldonline
Premium Leisure Corp. (PLC) grew its attributable profit by 83% in 2017, fueled by stronger gaming revenues from City of Dreams Manila.
PLC

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to PSE:PLC / Premium Leisure Corp. on message board site Silicon Investor.

AZN: AstraZeneca PLC AZN: AstraZeneca PLC AZN: AstraZeneca PLC Arris International PLC (ARRS) Arris International PLC (ARRS) Arris International PLC (ARRS)
CELTF Centamine PLC Mining u0026 Exploration CELTF Centamine PLC Mining u0026 Exploration CELTF Centamine PLC Mining u0026 Exploration ARM Holdings (Advanced RISC Machines) plc. ARM Holdings (Advanced RISC Machines) plc. ARM Holdings (Advanced RISC Machines) plc.
Autonomy Corporation plc (AUTNF.PK) Autonomy Corporation plc (AUTNF.PK) Autonomy Corporation plc (AUTNF.PK) Mallinckrodt Pharmaceuticals plc Mallinckrodt Pharmaceuticals plc Mallinckrodt Pharmaceuticals plc
Elan Corporation, plc (ELN) Elan Corporation, plc (ELN) Elan Corporation, plc (ELN) AMRN: Amarin Corporation plc AMRN: Amarin Corporation plc AMRN: Amarin Corporation plc
Renovo Plc. Renovo Plc. Renovo Plc. Hardy Underwriting Group Plc - good value stock Hardy Underwriting Group Plc - good value stock Hardy Underwriting Group Plc - good value stock